BRUCE G BROWN
Affiliation: University of Washington
- Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trialsB Greg Brown
Cardiology Division, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
Curr Opin Lipidol 17:631-6. 2006..Our analysis presents an alternative hypothesis to the prevailing view that low-density lipoprotein-C is the only important target of lipid therapy...
- Antioxidant vitamins and lipid therapy: end of a long romance?B Greg Brown
Department of Medicine, Division of Cardiology, University of Washington School of Medicine, Seattle, USA
Arterioscler Thromb Vasc Biol 22:1535-46. 2002..We conclude that they should rarely, if ever, be recommended for cardiovascular protection...
- Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study DesignB G Brown
Department of Medicine, University of Washington School of Medicine, Seattle, USA
Can J Cardiol 14:6A-13A. 1998..Based on these observations, a three-year angiographic study was proposed and received funding. Enrollment began in January 1995 and was completed in January 1997...
- Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burdenB G Brown
Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195, USA
Am J Cardiol 88:23E-26E. 2001..Agatston and calcium volume scores are comparably predictive of stenosis burden...
- Nicotinic acid, alone and in combinations, for reduction of cardiovascular riskB Greg Brown
Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195 8019, USA
Am J Cardiol 101:58B-62B. 2008..The widespread adoption of this strategy awaits the results of large, ongoing controlled clinical trials of HDL cholesterol raising...
- Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression?B Greg Brown
Cardiology Division, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195 8855, USA
J Am Coll Cardiol 49:933-8. 2007..Here, we review the evidence to date, discuss some of the concerns, and compare IVUS results with those of quantitative arteriography...
- Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemiaJohn R Guyton
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Am Coll Cardiol 51:1564-72. 2008..This study evaluated the safety and lipid-altering efficacy of ezetimibe/simvastatin (E/S) coadministered with extended-release niacin (N) in patients with type IIa or IIb hyperlipidemia...
- Reproducibility of carotid atherosclerotic lesion type characterization using high resolution multicontrast weighted cardiovascular magnetic resonanceBaocheng Chu
Department of Radiology, University of Washington Medical Center, Seattle, Washington 98195, USA
J Cardiovasc Magn Reson 8:793-9. 2006..Cardiovascular magnetic resonance (CMR) can characterize carotid atherosclerosis. The purpose of this study is to evaluate reader agreement of carotid atherosclerotic lesion types by CMR...
- Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular diseaseMarian C Cheung
Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA 98109 4517, USA
Biochim Biophys Acta 1762:131-7. 2006..These findings show for the first time that plasma PLTP activity is associated positively with CRP in CVD, a state of chronic inflammation...
- Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)Xue Qiao Zhao
Department of Medicine, Division of Cardiology, University of Washington School of Medicine, Seattle, Washington 98103, USA
Am J Cardiol 93:307-12. 2004..Thus, the simvastatin plus niacin regimen is effective, safe, and well tolerated in patients with or without diabetes mellitus...
- Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-AtheroscleroXue Qiao Zhao
Department of Medicine, Division of Cardiology, University of Washington School of Medicine, Seattle, Washington, USA
Am J Cardiol 104:1457-64. 2009..Greater stenosis progression rate is associated with a higher event rate. LDL cholesterol-lowering and HDL cholesterol-increasing therapies independently and significantly decrease coronary stenosis progression and decrease CV events...
- Expert commentary: niacin safetyB Greg Brown
Department of Cardiology, University of Washington School of Medicine, Seattle, Washington 98195, USA
Am J Cardiol 99:32C-34C. 2007
- Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDLTimothy S E Albert
Department of Medicine, University of Washington, Seattle, WA, USA
J Lipid Res 46:469-74. 2005..In conclusion, we found TG and HG to be the strongest predictors of apoL-I within a dyslipidemic CAD population. These data provide further characterization of the novel HDL-associated apoL-I...
- Coronary collateral size, flow capacity, and growth: estimates from the angiogram in patients with obstructive coronary diseaseJulia Rockstroh
Department of Medicine, Cardiology Division, University of Washington School of Medicine, Seattle, WA 98195, USA
Circulation 105:168-73. 2002..Stimulation of coronary collateral growth has potential clinical value, yet techniques to assess such growth in patients are limited...